Astrocytoma IDH-mutant Grade 4

• Peripheral biomarkers predict survival in patients with glioblastoma treated with temozolomide
• Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma: utility for detection versus monitoring
• Impact of Infection on Survival Outcomes in High-Grade Gliomas: A Retrospective Analysis of 26 Cases in Our Fifteen-Year Experience-Janus Faced Phenomenon
• Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis
• Surgical outcomes in high-grade adult type diffuse gliomas (ATDG) with a previous diagnosis of anaplastic astrocytoma without adjuvant therapy
• A series of 309 awake surgeries with transcortical approach for IDH-mutant low-grade glioma involving the insula: long-term onco-functional outcomes in 253 consecutive patients
• Management and survival trends for diffuse gliomas diagnosed at a single neurooncology center in China during 2000 to 2020
• Adoption of the T2-FLAIR Mismatch Sign Among Radiologists: How Well Are We Doing?

The World Health Organization Classification of Tumors of the Central Nervous System 2021 defined IDH-mutant Astrocytoma, Grade 4. However, the understanding of this subtype is still limited. Chen et al. from the Peking Union Medical College Hospital conducted a study to describe the features of astrocytoma, IDH-mutant, and Grade 4, and explored the similarities and differences between histological and molecular subtypes.

Patients who underwent surgery from January 2011 to January 2022, classified as astrocytoma, IDH-mutant, Grade 4 were included in this study. Clinical, radiological, histopathological, molecular pathological, and survival data were collected for analysis.

Altogether 33 patients with astrocytoma, IDH-mutant, Grade 4 were selected, including 20 with histological and 13 with molecular WHO Grade 4 astrocytoma. Tumor enhancement, intratumoral-necrosis like presentation, larger peritumoral edema, and more explicit tumor margins were frequently observed in histological WHO Grade 4 astrocytoma. Additionally, molecular WHO Grade 4 astrocytoma showed a tendency for relatively longer overall survival, while a statistical significance was not reached (47 vs. 25 months, p = 0.22). TP53, CDK6, and PIK3CA alteration was commonly observed, while PIK3R1 (p = 0.033), Notch1 (p = 0.027), and Mycn (p = 0.027) alterations may affect the overall survival of molecular WHO Grade 4 astrocytomas.

The study scrutinized IDH-mutant, Grade 4 astrocytoma. Therefore, further classification should be considered as the prognosis varied between histological and molecular WHO Grade 4 astrocytomas. Notably, therapies aiming at PIK3R1, Notch1, and Mycn may be beneficial ¹⁾.